{"DataElement":{"publicId":"6790106","version":"1","preferredName":"Kidney Carcinoma Immunotherapy Type","preferredDefinition":"Text term to identify an immunotherapy agent administered to an individual with renal cancer.","longName":"KID_IMMUNOTX_TYP","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6789097","version":"1","preferredName":"Kidney Carcinoma Immunotherapy","preferredDefinition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms._Therapy designed to induce changes in a patient's immune status in order to treat disease.","longName":"3201550v1.0:2704264v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3201550","version":"1","preferredName":"Renal Carcinoma","preferredDefinition":"A carcinoma arising from the epithelium of the renal parenchyma (renal cell carcinoma) or the renal pelvis (renal pelvis carcinoma).  The vast majority of renal cell carcinomas are adenocarcinomas.  The vast majority of renal pelvis carcinomas are transit","longName":"C9384","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Carcinoma","conceptCode":"C9384","definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E241B3C-89F4-11DA-E040-BB89AD437FA3","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-10","modifiedBy":"ONEDATA","dateModified":"2011-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2704264","version":"1","preferredName":"Immunotherapy","preferredDefinition":"(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments.","longName":"C15262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40162670-83EA-10B7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2007-11-29","modifiedBy":"ONEDATA","dateModified":"2007-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BDEE2BD-9252-715A-E053-F662850A2E93","latestVersionIndicator":"Yes","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"COOPERM","dateModified":"2019-07-11","changeDescription":"Curated to support Renal Cancer content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6078830","version":"2","preferredName":"Immunotherapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6078830v2.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"150","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Specify Other","ValueMeaning":{"publicId":"2770998","version":"1","preferredName":"Specify Other","longName":"2770998","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53F45DBF-5E42-1D6F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"MAESKEB","dateCreated":"2008-08-08","modifiedBy":"COOPERM","dateModified":"2018-02-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D102-65C0-E053-F662850AF3F1","beginDate":"2018-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D10C-65C0-E053-F662850AF3F1","beginDate":"2018-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D116-65C0-E053-F662850AF3F1","beginDate":"2018-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D120-65C0-E053-F662850AF3F1","beginDate":"2018-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D12A-65C0-E053-F662850AF3F1","beginDate":"2018-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D13B-65C0-E053-F662850AF3F1","beginDate":"2018-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Avelumab","valueDescription":"Avelumab","ValueMeaning":{"publicId":"5799363","version":"1","preferredName":"Avelumab","longName":"5799363","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B00-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6DD684E6-D145-65C0-E053-F662850AF3F1","beginDate":"2018-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"ONEDATA","dateModified":"2018-06-04","deletedIndicator":"No"},{"value":"Talimogene laherparepvec","valueDescription":"Talimogene Laherparepvec","ValueMeaning":{"publicId":"6365953","version":"1","preferredName":"Talimogene Laherparepvec","longName":"6365953","preferredDefinition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talimogene Laherparepvec","conceptCode":"C61314","definition":"An ICP34.5, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) based on the JS1 strain, and encoding the immunostimulating factor human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon intratumoral injection, talimogene laherparepvec selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7171C6E5-4544-56AE-E053-F662850A2A3A","latestVersionIndicator":"Yes","beginDate":"2018-07-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-07-20","modifiedBy":"COOPERM","dateModified":"2018-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75797F3C-CD7E-60E0-E053-F662850A220B","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","deletedIndicator":"No"},{"value":"Interleukin-2","valueDescription":"Recombinant Interleukin-2","ValueMeaning":{"publicId":"5799366","version":"1","preferredName":"Recombinant Interleukin-2","longName":"5799366","preferredDefinition":"One of a group of related proteins made by leukocytes (white blood cells) and other cells in the body. Interleukin-2 is made by a type of T lymphocyte. It increases the growth and activity of other T lymphocytes and B lymphocytes, and affects the development of the immune system. Aldesleukin (interleukin-2 made in the laboratory) is being used as a biological response modifier to boost the immune system in cancer therapy. Interleukin-2 is a type of cytokine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Interleukin-2","conceptCode":"C587","definition":"Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B55-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75797F3C-CD92-60E0-E053-F662850A220B","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","deletedIndicator":"No"},{"value":"Interferon-alpha","valueDescription":"Recombinant Interferon Alfa-2a","ValueMeaning":{"publicId":"6428121","version":"1","preferredName":"Recombinant Interferon Alfa-2a","longName":"6428121","preferredDefinition":"A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Interferon Alfa-2a","conceptCode":"C1952","definition":"A non-glycosylated recombinant human alpha interferon, subtype 2a, produced in the bacterium E. coli.  Interferon alpha-2a binds to its specific cell-surface receptor, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune modulating effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75797F3C-CD9E-60E0-E053-F662850A220B","latestVersionIndicator":"Yes","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75797F3C-CDB7-60E0-E053-F662850A220B","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","deletedIndicator":"No"},{"value":"Imiquimod","valueDescription":"Imiquimod","ValueMeaning":{"publicId":"3228300","version":"1","preferredName":"Imiquimod","longName":"3228300","preferredDefinition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imiquimod","conceptCode":"C1431","definition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15930B7-34E0-8C0F-E040-BB89AD43469C","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75797F3C-CDC1-60E0-E053-F662850A220B","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","deletedIndicator":"No"},{"value":"Bacille Calmette-Guerin vaccine","valueDescription":"BCG Vaccine","ValueMeaning":{"publicId":"5654664","version":"1","preferredName":"BCG Vaccine","longName":"5654664","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E22FDA-53D4-0E13-E053-F662850AD9C8","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75797F3C-CDD5-60E0-E053-F662850A220B","beginDate":"2018-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-09","modifiedBy":"ONEDATA","dateModified":"2018-09-09","deletedIndicator":"No"},{"value":"Provenge","valueDescription":"APC8015 Vaccine","ValueMeaning":{"publicId":"3439565","version":"1","preferredName":"APC8015 Vaccine","longName":"3439565v1.00","preferredDefinition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sipuleucel-T","conceptCode":"C1985","definition":"A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0C4833-1C2E-5DC6-E040-BB89AD434EEE","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-19","modifiedBy":"GDEEN","dateModified":"2023-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1B4EA-FDF5-0B34-E053-F662850AA93F","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Durvalumab plus Tremelimumab","valueDescription":"Durvalumab And Tremelimumab","ValueMeaning":{"publicId":"6788668","version":"1","preferredName":"Durvalumab And Tremelimumab","longName":"6788668","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BDB02C1-FDFC-20E0-E053-F662850AAFC4","latestVersionIndicator":"Yes","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDB02C1-FE15-20E0-E053-F662850AAFC4","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"Pembrolizumab plus Ipilimumab","valueDescription":"Pembrolizumab And Tremelimumab","ValueMeaning":{"publicId":"6788669","version":"1","preferredName":"Pembrolizumab And Tremelimumab","longName":"6788669","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BDB02C1-FE23-20E0-E053-F662850AAFC4","latestVersionIndicator":"Yes","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDB02C1-FE3C-20E0-E053-F662850AAFC4","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"Tremelimumab","valueDescription":"Tremelimumab","ValueMeaning":{"publicId":"3185137","version":"1","preferredName":"Tremelimumab","longName":"3185137","preferredDefinition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A317-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDB02C1-FE46-20E0-E053-F662850AAFC4","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"Cemiplimab","valueDescription":"Cemiplimab","ValueMeaning":{"publicId":"6687982","version":"1","preferredName":"Cemiplimab","longName":"6687982","preferredDefinition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cemiplimab","conceptCode":"C121540","definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86084999-63D2-7CF3-E053-F662850ABF0E","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8BDB02C1-FE50-20E0-E053-F662850AAFC4","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","deletedIndicator":"No"},{"value":"IL-2","valueDescription":"Interleukin-2","ValueMeaning":{"publicId":"5235366","version":"1","preferredName":"Interleukin-2","longName":"5235366","preferredDefinition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3168829E-C941-6B0F-E050-BB89AD436CC0","latestVersionIndicator":"Yes","beginDate":"2016-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C1A9038-148C-4378-E053-F662850AB49B","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"Interferon","ValueMeaning":{"publicId":"3119698","version":"1","preferredName":"Interferon","longName":"3119698","preferredDefinition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AE1E2A1-466C-6C31-E040-BB89AD434C6B","latestVersionIndicator":"Yes","beginDate":"2010-07-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C1A9038-1497-4378-E053-F662850AB49B","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Bevacizumab and interferon","valueDescription":"Bevacizumab/Interferon Alfa Regimen","ValueMeaning":{"publicId":"6790108","version":"1","preferredName":"Bevacizumab/Interferon Alfa Regimen","longName":"6790108","preferredDefinition":"A regimen consisting of bevacizumab and interferon-alfa that can be used for the treatment of advanced renal cell carcinoma (RCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab/Interferon Alfa Regimen","conceptCode":"C12075","definition":"A regimen consisting of bevacizumab and interferon-alfa that can be used for the treatment of advanced renal cell carcinoma (RCC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C1A9038-14A6-4378-E053-F662850AB49B","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"COOPERM","dateModified":"2019-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C1A9038-14BF-4378-E053-F662850AB49B","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Pembrolizumab and Axitinib","valueDescription":"Axitinib/Pembrolizumab Regimen","ValueMeaning":{"publicId":"6790110","version":"1","preferredName":"Axitinib/Pembrolizumab Regimen","longName":"6790110","preferredDefinition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of advanced renal cell carcinoma (RCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib/Pembrolizumab Regimen","conceptCode":"C162220","definition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C1A9038-14CE-4378-E053-F662850AB49B","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"COOPERM","dateModified":"2019-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C1A9038-14E7-4378-E053-F662850AB49B","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Nivolumab/Ipilimumab","valueDescription":"Ipilimumab and Nivolumab Regimen","ValueMeaning":{"publicId":"6409150","version":"1","preferredName":"Ipilimumab and Nivolumab Regimen","longName":"6409150","preferredDefinition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab/Nivolumab Regimen","conceptCode":"C154272","definition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone cancer, kidney cancer, colorectal cancer, melanoma, non-small cell lung cancer (NSCLC), and malignant pleural/peritoneal mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-661C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"SOKKERL","dateModified":"2019-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C1A9038-14FB-4378-E053-F662850AB49B","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Pembrolizumab and Axitinib","valueDescription":"Axitinib/Pembrolizumab Regimen","ValueMeaning":{"publicId":"6813211","version":"1","preferredName":"Axitinib/Pembrolizumab Regimen","longName":"6813211","preferredDefinition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of advanced renal cell carcinoma (RCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib/Pembrolizumab Regimen","conceptCode":"C162220","definition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCBCF1B-3EC6-3BEC-E053-F662850A5044","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CCBCF1B-3EDE-3BEC-E053-F662850A5044","beginDate":"2019-07-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","deletedIndicator":"No"},{"value":"Filgrastim","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"3379062","version":"1","preferredName":"Filgrastim","longName":"3379062","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AD83-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95FB5822-8C12-5F2C-E053-F662850AB485","beginDate":"2019-10-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-28","modifiedBy":"ONEDATA","dateModified":"2019-10-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6DD684E6-D0EC-65C0-E053-F662850AF3F1","latestVersionIndicator":"Yes","beginDate":"2018-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-06-04","modifiedBy":"HARTLEYG","dateModified":"2019-10-28","changeDescription":"Created for Lung request 2.20.18 mc Versioned to remove Lung from Long Name to make this reusable for AVC request 5.16.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"6788377","version":"1","longName":"Renal Cancer","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Immunotherapy","type":"Preferred Question Text","description":"Immunotherapy","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C1A7943-EDCB-4A16-E053-F662850AE725","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"COOPERM","dateModified":"2019-07-11","changeDescription":"Curated to support Renal Cancer content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}